openFDA
Cure8 regulatory brief
ABRILADA FDA label update (2026-06-18)
Medications
Adalimumab
Anti-TNF
Regulatory Update
Adult patients
Pediatric Patients
Clinicians
Crohn's disease
Why This Matters
This FDA label update adds or confirms ABRILADA (an adalimumab product) as an approved TNF-blocker option for Crohn’s disease (including children ≥6) and ulcerative colitis (adults). It emphasizes infection and malignancy risks that matter for people starting or taking TNF blockers.
Who Should Pay Attention
Adults and pediatric patients with Crohn's disease or ulcerative colitis, caregivers of pediatric patients, and clinicians who prescribe biologic therapies for IBD.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
The update is a drug-label (regulatory) record for ABRILADA, an adalimumab biosimilar/adalimumab product. It confirms approved uses across several autoimmune conditions including moderately to severely active Crohn’s disease (adults and children ≥6 years) and ulcerative colitis (adults).
The label highlights important safety information: a boxed warning about increased risk of serious infections (including TB and invasive fungal infections) and reports of malignancies associated with TNF blockers. It advises testing for latent TB prior to initiation and monitoring for infections during treatment.
If you or a caregiver are considering or taking ABRILADA, discuss screening for latent TB and other infection-risk measures, and review the full prescribing information with your clinician.
Keep In Mind
This is a regulatory drug-label document (DailyMed) summarizing approved indications and safety warnings. It is not a clinical trial report; patients should consult their prescribing clinician and review the full label for dosing, contraindications, and monitoring details.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedJun 18, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Adalimumab FDA label update (2026-07-08)
The label confirms adalimumab is approved for Crohn’s disease and ulcerative colitis and includes boxed safety warnings—information that directly affects patients considering or taking this TNF‑blocking biologic.
A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease - Dove Medical Press
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
When are biologic drugs an option for Crohn’s disease?
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.